ArticleCell reports2026
Depletion of CARM1 slows in vivo tumorigenicity and rewires developmental programming in glioma stem-like cells.
Article in Cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
Abstract
Glioma stem-like cells (GSCs) exploit developmental signaling programs that contribute to glioblastoma heterogeneity and therapy resistance. Here, we define a role for the arginine methyltransferase coactivator-associated arginine methyltransferase 1 (CARM1) in regulating GSC lineage state and survival signaling. CARM1 depletion slows GSC growth, increases apoptosis, alters histone post-translational modifications, and shifts transcriptomic and proteomic profiles toward a radial glial-like state. Loss of CARM1 increases NGFR/NTRK signaling and sensitizes GSCs to NTRK and AKT inhibition. Mechanistically, NFIA is a CARM1 substrate, and mutation of NFIA arginine 389 increases NGFR expression, supporting a role for CARM1-dependent NFIA methylation in NGFR repression. In orthotopic xenografts, CARM1 depletion reduces tumor burden and prolongs survival. These findings identify CARM1 as a regulator of GSC developmental programs and NGFR/NTRK-dependent survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.